分析师对贝莱特生物保持"买入"评级, 目标价格为100美元, Analysts maintain a "buy" rating on Belite Bio, setting a target price of $100, despite a current EPS loss.

Cantor Fitzgerald和HC Wainwright都重申了对Belite Bio(BLTE)的“买”评级,目标价格为100美元,而基准则将其价格目标提高到79美元。 Cantor Fitzgerald and HC Wainwright have both reaffirmed a "buy" rating on Belite Bio (BLTE) with a $100 target price, while Benchmark raised its price target to $79. 尽管报告EPS损失了0.32美元,但估计损失为0.02美元,分析家预计该年度的EPS损失为-1.17美元。 Despite reporting an EPS loss of $0.32, missing estimates by $0.02, analysts anticipate a -1.17 EPS for the year. 生物制药公司Belite Bio正在针对视网膜疾病开发LBS-008。 Belite Bio, a biopharmaceutical company, is developing LBS-008 for retinal diseases. 股票开放额67.81美元,市场上限为21.6亿美元。 The stock opened at $67.81 with a market cap of $2.16 billion.